Australian-based Immuron Limited has signed a strategic investment

Australian-based Immuron Limited has signed a strategic investment and option agreement with Ateria Health Limited that can reach over 5 million dollars when it is all said and done.
Ateria has developed and recently launched a ground-breaking product for the treatment of irritable bowel syndrome (IBS).